Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

3:26pm IST
Change (% chg)

-0.70p (-0.39%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VEC.L


Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to... (more)


Beta: 0.35
Market Cap(Mil.): £731.38
Shares Outstanding(Mil.): 406.55
Dividend: --
Yield (%): --


  VEC.L Industry Sector
P/E (TTM): 219.93 35.45 35.59
EPS (TTM): 0.01 -- --
ROI: 1.38 15.51 14.96
ROE: 1.65 16.08 15.84
Search Stocks

BRIEF-Vectura says had pre-IND meeting with FDA on asthma treatment for children

* Announces successful pre-ind meeting with US FDA regarding vr647

28 Jul 2015

Vectura Group appoints AstraZeneca executive as CEO

June 24 - Respiratory drugs specialist Vectura Group Plc appointed AstraZeneca executive James Ward-Lilley as chief executive officer effective Oct. 1.

24 Jun 2015

BRIEF-Vectura appoints James Ward-Lilley as CEO

* Announces appointment of James Ward-Lilley as CEO and executive director. James will succeed Dr Chris Blackwell who, as previously announced, leaves Vectura at end of June 2015

24 Jun 2015

BRIEF-FTSE says Spirit Pub to be deleted from 250 index, Vectura added

* Vectura Group (UK, B01D1K4) will be added to FTSE 250 index

18 Jun 2015

Vectura revenue jumps 59 pct, beats estimates

May 20 - Respiratory drugs specialist Vectura Group Plc reported a bigger-than-expected jump in full-year revenue as it raked in higher royalty payments and licensing revenue.

20 May 2015

BRIEF-Vectura Group FY revenue up 59 pct to 58 mln stg

* Revenues up 59 pct to 58 mln stg (2013/14: 36.5 mln stg) from increased royalties and milestone payments

20 May 2015

BRIEF-Vectura says to close site in Gem√ľnden, Germany

* Intention to close its site in Gem√ľnden, germany, effective by March 2016

14 Apr 2015

BRIEF-Vectura says NDAs for QVA149 and NVA237 accepted by FDA

* Acceptances trigger milestone payments to Vectura of $12.5 mln and $7.5 mln respectively Source text for Eikon: Further company coverage:

05 Mar 2015

Earnings vs. Estimates

Search Stocks